PMID: 16615854Apr 18, 2006Paper

Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions

Biochemistry. Biokhimii︠a︡
E I GoufmanA I Archakov

Abstract

One of the problems of plasma proteomics is a presence of large major components. In this work, we use the thermostable fraction as a way to deplete these major proteins. The thermostable fraction of serum samples from patients with ovarian, uterus, and breast cancers and benign ovarian tumor was analyzed using two-dimensional electrophoresis combined with MALDI-TOF(-TOF)-mass spectrometry. Of them, alpha-1-acid glycoprotein and clusterin are expressly down-regulated in breast cancer, whereas transthyretin is decreased specifically in ovarian cancer. Apolipoprotein A-I forms have decreased spot volumes, while haptoglobin alpha1, in contrast, is elevated in several tumors. These data are partly consistent with previous art studies on cancer proteomics, which involve mass-spectrometry-based serum profiling techniques. Serum thermostable fraction may be recommended as a good tool for medium and small protein proteome investigation, in particular, by 2D-electrophoresis.

References

Oct 29, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·J C DuchéJ P Tillement
Jul 29, 2000·Clinical Biochemistry·J C DuchéJ Barré
Feb 28, 2002·Lancet·Emanuel F PetricoinLance A Liotta
Dec 19, 2002·Molecular & Cellular Proteomics : MCP·N Leigh Anderson, Norman G Anderson
Mar 28, 2003·Analytical Chemistry·Jan HavlisAndrej Shevchenko
May 20, 2003·Molecular & Cellular Proteomics : MCP·Laura F SteelTimothy Block
Oct 31, 2003·Nature·Lance A LiottaEmanuel Petricoin
Jan 20, 2004·Proteomics·Rulin ZhangGeorge Jackowski
Apr 23, 2004·Current Opinion in Biotechnology·Emanuel F Petricoin, Lance A Liotta

❮ Previous
Next ❯

Citations

Jan 6, 2009·Biochemistry. Biokhimii︠a︡·Lan-Tu GouYu-Quan Wei
Apr 15, 2008·Future Oncology·François Bertucci, Anthony Goncalves
Apr 5, 2011·Bioorganicheskaia khimiia·I A DeminaV M Govorun
Jun 29, 2007·FEBS Letters·Baocun SunXinghong Jia
Feb 5, 2013·Biochimica Et Biophysica Acta·Kuo-Hsun ChiuPao-Chi Liao
Jan 1, 2009·Proteomics. Clinical Applications·Magnus PalmbladRainer Cramer
Sep 1, 2011·Mass Spectrometry Reviews·Peihong ZhuJohn G Marshall
Sep 5, 2015·BioMed Research International·Andrea ManniJose Russo
Apr 5, 2007·Molecular Cancer·William C S Cho
Feb 15, 2017·Proteomics. Clinical Applications·Somchai ChutipongtanateJisnuson Svasti
May 31, 2006·Molecular & Cellular Proteomics : MCP·François BertucciAnthony Goncalves
Sep 1, 2007·Proteomics. Clinical Applications·José Bermúdez-Crespo, José Luis López
Sep 1, 2007·Proteomics. Clinical Applications·Marta Lomnytska, Serhiy Souchelnytskyi
Jun 12, 2010·Expert Review of Proteomics·Oxana TrifonovaAlexander Archakov
Jul 17, 2012·Bioorganicheskaia khimiia·N N IbragimovaT A Gorshkova
Mar 25, 2019·Bulletin of Experimental Biology and Medicine·I E GoufmanK B Gershkovich
May 20, 2014·Biomedit︠s︡inskai︠a︡ khimii︠a︡·S N TamkovichP P Laktionov
Jul 16, 2014·Biomedit︠s︡inskai︠a︡ khimii︠a︡·S N NaryzhnyĭM V Filatov
Jun 12, 2019·BioMed Research International·Wararat ChiangjongSomchai Chutipongtanate
Sep 7, 2017·Molecular Carcinogenesis·Deepshikha P KatareSwatantra K Jain
Mar 6, 2010·Bulletin du cancer·Marine GilabertAnthony Gonçalves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.